At the time of writing, Intellia Therapeutics Inc [NTLA] stock is trading at $11.01, up 10.76%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The NTLA shares have gain 13.10% over the last week, with a monthly amount drifted -8.40%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Intellia Therapeutics Inc [NASDAQ: NTLA] stock has seen the most recent analyst activity on February 23, 2024, when Goldman downgraded its rating to a Neutral and also revised its price target to $32 from $136. On April 13, 2023, Canaccord Genuity initiated with a Buy rating and assigned a price target of $66 on the stock. Bernstein started tracking the stock assigning a Outperform rating and suggested a price target of $54 on March 21, 2023. BMO Capital Markets upgraded its rating to a Outperform and raised its price target to $57 on March 14, 2023. Cantor Fitzgerald started tracking with a Overweight rating for this stock on February 01, 2023, and assigned it a price target of $67. In a note dated January 24, 2023, Citigroup upgraded an Neutral rating on this stock and revised its target price from $48 to $39.
For the past year, the stock price of Intellia Therapeutics Inc fluctuated between $9.25 and $34.87. Currently, Wall Street analysts expect the stock to reach $44 within the next 12 months. Intellia Therapeutics Inc [NASDAQ: NTLA] shares were valued at $11.01 at the most recent close of the market. An investor can expect a potential return of 299.64% based on the average NTLA price forecast.
Analyzing the NTLA fundamentals
According to Intellia Therapeutics Inc [NASDAQ:NTLA], the company’s sales were 43.09M for trailing twelve months, which represents an -24.02% plunge. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at -12.48%, Pretax Profit Margin comes in at -12.12%, and Net Profit Margin reading is -12.12%. To continue investigating profitability, this company’s Return on Assets is posted at -0.45, Equity is -0.52 and Total Capital is -0.5. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.18 points at the first support level, and at 9.35 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.47, and for the 2nd resistance point, it is at 11.94.
Ratios To Look Out For
It is important to note that Intellia Therapeutics Inc [NASDAQ:NTLA] has a current ratio of 6.73. Further, the Quick Ratio stands at 6.73, while the Cash Ratio is 1.14. Considering the valuation of this stock, the price to sales ratio is 26.02, the price to book ratio is 1.16.
Transactions by insiders
Recent insider trading involved Dube Michael P, VP, Chief Accounting Officer, that happened on Jan 03 ’25 when 1372.0 shares were sold. EVP, General Counsel, BASTA JAMES completed a deal on Jan 03 ’25 to sell 7074.0 shares. Meanwhile, EVP, Chief Medical Officer Lebwohl David sold 9557.0 shares on Jan 03 ’25.
